Heart Failure Reviews

, Volume 13, Issue 4, pp 425–430 | Cite as

Anemia treatment in chronic kidney disease: shifting uncertainty

  • Marc A. Pfeffer


Epidemiologic observations showing associations between higher levels of some biologic markers such as blood pressure and serum cholesterol with heightened risk of death and non-fatal cardiovascular events have provided important data to develop hypotheses regarding pharmacologic therapies to modify these markers to improve prognosis. Randomized controlled trials have shown that strategies to reduce blood pressure with a variety of antihypertensive agents and LDL cholesterol with statins do, indeed, result in important improvements in clinical outcomes. However, there are several instances where a hypothesis based on strong observational data has been rejected based on surprising counterintuitive evidence generated from randomized controlled clinical trials. Use of inotropic therapies for patients with reduced left ventricular ejection fraction heart failure, administration of class I antiarrhythmic agents to suppress ventricular arrhythmias in high-risk patients, and use of hormone replacement therapy for postmenopausal women have each shown that therapies presumed to be of benefit may actually be producing unfavorable clinical results. Use of erythropoietic stimulating agents (ESA) in chronic kidney disease patients with anemia is similarly based on strong observational data indicating that the degree of anemia is independently associated with higher risk for cardiovascular morbidity and mortality. In non-dialysis patients with mild to moderate anemia, current clinical outcome studies have only addressed arbitrary hemoglobin targets for ESA therapy and have shown that targeting the higher hemoglobin levels was not associated with the benefit and may even result in harm. This review will outline the importance of having a placebo-controlled trial in this patient population to better assess the risk benefit profile of this therapy.


Erythropoietin stimulating agents Randomized controlled clinical trials Anemia Chronic kidney disease 


  1. 1.
    Devereaux PJ, Yusuf S (2003) The evolution of the randomized controlled trial and its role in evidence-based decision making. J Intern Med 254:105–113PubMedCrossRefGoogle Scholar
  2. 2.
    Califf RM, DeMets DL (2002) Principles from clinical trials relevant to clinical practice: Part I. Circulation 106:1015–1021PubMedCrossRefGoogle Scholar
  3. 3.
    Califf RM, DeMets DL (2002) Principles from clinical trials relevant to clinical practice: Part II. Circulation 106:1172–1175PubMedCrossRefGoogle Scholar
  4. 4.
    Scandinavian Simvastatin Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383–1389Google Scholar
  5. 5.
    Baigent C, Keech A, Kearney PM et al (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366:1267–1278PubMedCrossRefGoogle Scholar
  6. 6.
    Fleming TR, DeMets DL (1996) Surrogate end points in clinical trials: are we being misled? Ann Intern Med 125:605–613PubMedGoogle Scholar
  7. 7.
    Ioannidis JP (2005) Contradicted and initially stronger effects in highly cited clinical research. JAMA 294:218–228PubMedCrossRefGoogle Scholar
  8. 8.
    Echt DS, Liebson PR, Mitchell LB et al (1991) Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 324:781–788PubMedGoogle Scholar
  9. 9.
    van Veldhuisen DJ, Poole-Wilson PA (2001) The underreporting of results and possible mechanisms of ‘negative’ drug trials in patients with chronic heart failure. Int J Cardiol 80:19–27PubMedCrossRefGoogle Scholar
  10. 10.
    Cohn JN, Goldstein SO, Greenberg BH et al (1998) A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N Engl J Med 339:1810–1816PubMedCrossRefGoogle Scholar
  11. 11.
    The effect of diltiazem on mortality and reinfarction after myocardial infarction (1988) The multicenter diltiazem postinfarction trial research group. N Engl J Med 319:385–392Google Scholar
  12. 12.
    Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333PubMedCrossRefGoogle Scholar
  13. 13.
    Astor BC, Muntner P, Levin A, Eustace JA, Coresh J (2002) Association of kidney function with anemia: the Third National Health and Nutrition Examination Survey (1988–1994). Arch Intern Med 162:1401–1408PubMedCrossRefGoogle Scholar
  14. 14.
    Stevens LA, Coresh J, Greene T, Levey AS (2006) Assessing kidney function—measured and estimated glomerular filtration rate. N Engl J Med 354:2473–2483PubMedCrossRefGoogle Scholar
  15. 15.
    Weiner DE, Tighiouart H, Vlagopoulos PT et al (2005) Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease. J Am Soc Nephrol 16:1803–1810PubMedCrossRefGoogle Scholar
  16. 16.
    Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH (2004) Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 164:659–663PubMedCrossRefGoogle Scholar
  17. 17.
    Abramson JL, Jurkovitz CT, Vaccarino V, Weintraub WS, McClellan W (2003) Chronic kidney disease, anemia, and incident stroke in a middle-aged, community-based population: the ARIC Study. Kidney Int 64:610–615PubMedCrossRefGoogle Scholar
  18. 18.
    Locatelli F, Pisoni RL, Combe C et al (2004) Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 19:121–132PubMedCrossRefGoogle Scholar
  19. 19.
    McCullough PA, Lepor NE (2005) Piecing together the evidence on anemia: the link between chronic kidney disease and cardiovascular disease. Rev Cardiovasc Med 6:S4–S12PubMedGoogle Scholar
  20. 20.
    Foley RN, Parfrey PS, Morgan J et al (2000) Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 58:1325–1335PubMedCrossRefGoogle Scholar
  21. 21.
    Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW (1987) Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 316:73–78PubMedGoogle Scholar
  22. 22.
  23. 23.
    Cannella G, La Canna G, Sandrini M et al (1991) Reversal of left ventricular hypertrophy following recombinant human erythropoietin treatment of anaemic dialysed uraemic patients. Nephrol Dial Transplant 6:31–37PubMedGoogle Scholar
  24. 24.
    Besarab A, Bolton WK, Browne JK et al (1998) The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339:584–590PubMedCrossRefGoogle Scholar
  25. 25.
    Steinbrook R (2006) Haemoglobin concentrations in chronic kidney disease. Lancet 368:2191–2193PubMedCrossRefGoogle Scholar
  26. 26.
    Cody J, Daly C, Campbell M et al (2005) Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients. Cochrane Database Syst Rev 3:CD003266PubMedGoogle Scholar
  27. 27.
    Collins AJ (2003) The hemoglobin link to adverse outcomes. Adv Stud Med 3:S194–S197Google Scholar
  28. 28.
    Heeschen C, Aicher A, Lehmann R et al (2003) Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 102:1340–1346PubMedCrossRefGoogle Scholar
  29. 29.
    Goldschmidt-Clermont P, Diehl A (2005) Arterial homeostasis, inflammation, and erythropoietic growth factors. Rev Cardiovasc Med 6:S22–S26PubMedGoogle Scholar
  30. 30.
    Ingelfinger JR (2007) Through the looking glass: anemia guidelines, vested interests, and distortions. [Editorial]. Clin J Am Soc Nephrol 2:415–417PubMedCrossRefGoogle Scholar
  31. 31.
    Steinbrook R (2007) Medicare and erythropoietin. N Engl J Med 356:4–6PubMedCrossRefGoogle Scholar
  32. 32.
    Drueke TB, Locatelli F, Clyne N et al (2006) Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355:2071–2084PubMedCrossRefGoogle Scholar
  33. 33.
    Singh AK, Szczech L, Tang KL et al (2006) Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355:2085–2098PubMedCrossRefGoogle Scholar
  34. 34.
    Phrommintikul A, Haas SJ, Elsik M, Krum H (2007) Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 369:381–388PubMedCrossRefGoogle Scholar
  35. 35.
    Leyland-Jones B (2003) Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4:459–460PubMedCrossRefGoogle Scholar
  36. 36.
    FDA Alert. Information for healthcare professionals: erythropoiesis stimulating agents (ESA) [Aranesp (darbepoetin), Epogen (epoetin alfa), and Procrit (epoetin alfa)]. Food and Drug Administration, Rockville, MD, March 9, 2007. Accessed 9 Aug 2007
  37. 37.
    American College of Cardiology (2007) Simon Dack lecture on “What Can We Expect From Clinical Trials in the 21st Century?”
  38. 38.
    Mix TC, Brenner RM, Cooper ME et al (2005) Rationale—Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J 149:408–413PubMedCrossRefGoogle Scholar
  39. 39.
    Pfeffer MA (2007) An ongoing study of anemia correction in chronic kidney disease. N Engl J Med 356:959–961PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  1. 1.Dzau Professor of Medicine, Harvard Medical School, Cardiovascular DivisionBrigham and Women’s HospitalBostonUSA

Personalised recommendations